CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
The latest in health news includes Zealand Pharma's obesity drug trial, a record dengue outbreak in the Americas, CervoMed's ...
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced ...
CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.
Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...